A treatment for children and adults with spinal muscular atrophy (SMA)
WHAT
COULD
SPINRAZA UNLOCK?
See the potential benefits Review the safety profile

A treatment for children
and adults with spinal
muscular atrophy (SMA)

Ian
age 36

Later-onset (Type 3) SMA treated with SPINRAZA


OVER 2 YEARS OF
REAL-WORLD EXPERIENCE

2600+ individuals with SMA have been treated with SPINRAZA in the US.* They range in age from 3 days to 79 years:

of individuals are adults

of individuals treated with SPINRAZA are in the maintenance dosing phase

of individuals who started on SPINRAZA remain on treatment

*Based on commercial patients in the US (including Puerto Rico) as of December 2018.
Includes clinical trial patients.
Clinical studies of SPINRAZA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger patients.

Stay connected

Sign up with us to receive the latest news, support information, and upcoming events.

Valid Email Required

Clinical studies

SPINRAZA was evaluated in a broad range of SMA types and levels of function

Sofia, a child with SMA Type 1

ENDEAR

Infantile-onset SMA

A well-controlled study of motor milestone achievement and survival in individuals with Type 1 SMA aged 30 to 262 days

See motor milestone results
James, an adult with Type 3 SMA

CHERISH and CS2/CS12

Later-onset SMA

Multiple studies of motor function changes in individuals with Types 2 and 3 SMA aged 2 to 16 years

See motor function results
Cameron, a child with Type 1 SMA

NURTURE

Presymptomatic SMA

A supportive, open-label study of developmental milestone achievement in infants diagnosed with SMA aged 3 to 42 days

See motor milestone results

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.

Unlocked:
SPINRAZA stories

Watch stories of the unlocked potential in individuals treated with SPINRAZA


Your circle of support

Find out how SMA360° can help with insurance and treatment logistics.*

*SMA360° services from Biogen are available only to those who have been prescribed SPINRAZA.
SMA360° is intended for US residents only.

IMPORTANT SAFETY INFORMATION

Increased risk of bleeding complications has been observed after administration of similar medicines. Your healthcare provider should perform blood tests before you start treatment with SPINRAZA and before each dose to monitor for signs of these risks. Seek medical attention if unexpected bleeding occurs.

Increased risk of kidney damage, including potentially fatal acute inflammation of the kidney, has been observed after administration of similar medicines. Your healthcare provider should perform urine testing before you start treatment with SPINRAZA and before each dose to monitor for signs of this risk.

The most common side effects of SPINRAZA include lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome.

These are not all of the possible side effects of SPINRAZA. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking SPINRAZA, tell your healthcare provider if you are pregnant or plan to become pregnant.

Please see full Prescribing Information.

As a courtesy, our full Prescribing Information is also available en Español. For prescribing decisions, please refer to official approved labeling.

This information is not intended to replace discussions with your healthcare provider.


INDICATION

SPINRAZA is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.